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Background: Nomograms are statistics-based tools that provide the overall probability of a specific outcome. In our
previous study, we developed a nomogram that predicts recurrence of early gastric cancer (EGC) after curative
resection. We carried out this study to externally validate our EGC nomogram.
Patients and methods: The EGC nomogram was established from a retrospective EGC database that included
2923 consecutive patients. This nomogram was independently externally validated for a cohort of 1058 consecutive
patients. For the EGC nomogram validation, we assessed both discrimination and calibration.
Results: Within the follow-up period (median 37 months), a total of 11 patients (1.1%) experienced recurrence. The
concordance index (c-index) was 0.7 (P = 0.02) and the result of the overall C index was 0.82 [P = 0.006, 95%
confidence interval (CI) 0.59–1.00]. The goodness of fit test showed that the EGC nomogram had significantly good fit for
1- and 2-year survival intervals (P = 0.998 and 0.879, respectively). The actual and predicted survival outcomes showed
good agreement, suggesting that the survival predictions from the nomogram are well calibrated externally.
Conclusions: A preexisting nomogram for predicting disease-free survival (DFS) of EGC after surgery was
externally validated. The nomogram is useful for accurate and individual prediction of DFS, patient prognostication,
counseling, and follow-up planning.
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introduction
Early gastric cancer (EGC) has been defined as an
adenocarcinoma that is confined to the mucosa or submucosa,
regardless of the size or presence of lymph node metastasis.
Recent developments in diagnosis and the introduction of
national mass screening programs have allowed increased
detection of EGC, and these patients account for 40%–50%
of operations carried out for gastric carcinoma in Japan and
Korea [1, 2]. Patients with EGC generally have an excellent
prognosis after curative resection (R0) with 5-year survival
rates of approximately 90%. However, recurrence can still
occur after curative resection of EGC, with a rate of 1.4%–7.0%
[3–8]. Some studies have evaluated the independent risk factors
for recurrence of EGC, but the number of patients with
recurrence in these studies was too small to provide reliable
results [6–9]. In particular, the prediction of recurrence of
EGC after R0 resection has not been studied.
We attempted to identify independent risk factors for
predicting recurrence of EGC after curative resection.
According to results of our previous study [10], elevated gross
type and presence of lymph node metastasis were shown to
be independent risk factors for overall recurrence. On the basis
of findings from this study, our institution developed
a nomogram that estimates the disease-specific survival rate
of each patient at 2, 5, and 10 years after curative resection
for EGC (Figure 1).
Nomograms are statistics-based tools that provide the overall
probability of a specific outcome [11]. In clinical practice, it is
important to predict prognosis in order to decide the further
treatment plan or follow-up duration. Nomograms, which can
incorporate more clinicopathologic parameters than the staging
system by reflecting not only the tumor characteristics but also
the host status, can provide the clinician with a better
estimation of the prognosis of an individual patient. Another
potential benefit of the nomogram is that, with a simple
graphical representation of a statistical predictive model, it
generates a numerical probability of a clinical event. However,
one should be cautious about extrapolating from regression
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models built on different populations because a nomogram
derived from one population may not be applicable to a new
population. Therefore, external validation is essential to ensure
that the nomogram is universally applicable in practice.
The aim of the present study was to externally validate this
EGC nomogram in patients from another independent data set.
materials and methods
patients
A patient cohort from the EGC database at the Department of Surgery and
Gastric Cancer Clinic, Yonsei University Health System (YUHS) in Seoul,
Korea, was used to evaluate the validity of the EGC nomogram. Between
May 2005 and April 2007, a consecutive series of 1058 patients with EGC
who underwent curative resection at the Severance Hospital, YUHS, were
retrospectively reviewed.
definitions
The variables required for the EGC nomogram were age, gender, tumor
size, location, gross type, histological differentiation, depth of invasion,
lymph node metastasis, and number of positive nodes. By using these
clinicopathogic factors, the practical usage of the EGC nomogram is
available in the Hyper Text Markup Language format shown in Figure 2.
The standard operation for EGC was a total or subtotal gastrectomy with
D2 lymph node dissection in accordance with the rules of the Japanese
Research Society for Gastric Cancer (JRSGC). Curative resection was
defined as no tumor remaining after removal, both macroscopically and
microscopically.
The gross appearance was classified according to JRSGC standard: type I
and IIa were regarded as elevated type; type IIb as flat type; and type IIc and
III as depressed type. A mixed type was recorded according to the type of
the largest area.
The histological type was classified into two main categories:
differentiated type, including papillary adenocarcinoma and well- and
moderately differentiated tubular adenocarcinoma, and undifferentiated
type, including poorly differentiated tubular adenocarcinoma, mucinous
adenocarcinoma, and signet ring cell adenocarcinoma.
After being discharged from the hospital, the patients were started on
a regular follow-up program. Patients were followed up every 3 months
during the first 2 years, every 4 months during the third year, every 6
months during the fourth and fifth years, and once every year thereafter.
Recurrence was confirmed by physical findings, radiological studies,
endoscopic examination with biopsy, and surgery if indicated. Disease that
recurred within 24 months from the time of the operation was defined as an
early recurrence. Disease-free survival (DFS) was defined as time of
operation to time of recurrence.
data analysis
The patients’ features and clinical characteristics were analyzed using the
two-tailed Student’s t-test for continuous variables and v2 test for
categorical variables. DFS was estimated using the Kaplan–Meier method.
Nomogram validation consisted of discrimination and calibration. First,
discrimination was quantified with the concordance index (c-index).
Discrimination refers to a nomogram model’s ability to correctly
distinguish the two classes of outcome. A model with good discrimination
ability produces higher predicted probabilities for subjects who had events
than for subjects who did not have events. The area under the Receiver
Operating Characteristic (ROC) curve is one of the most commonly used
measures for model discrimination. To further evaluate the discrimination
of the nomogram model, we considered a time-to-event-based survival time
model with censored observations such as the Cox regression model. Thus,
for our nomogram discrimination, we used the overall C index introduced
by Harrell as a natural extension of the ROC curve area to survival analysis
[12, 13]. Second, we assessed calibration that compares the predicted
Figure 1. Instructions of early gastric cancer nomogram. Find the position of each variable on the corresponding axis and draw a line to the ‘Points’ axis to
determine the number of points for each variable. Add the points for all the variables together and draw a line from the ‘Total points’ axis to determine the
survival probabilities at the bottom, assuming no death from other causes. DFS, disease-free survival.
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probability of DFS with the actual survival. We used a Poisson log-linear
model as an approximation to the survival time model in investigating the
asymptotic behavior of the statistic based on the framework of a goodness
of fit statistic for generalized linear models [12]. In addition, another
calibration measure was carried out by grouping patients according to their
nomogram-predicted probabilities and then comparing the mean of the
group with the observed Kaplan–Meier DFS estimate.
SPSS 17.0 (SPSS, Chicago, IL) was used for the statistical analyses. In all
statistical analyses, a P value <0.05 was considered significant.
results
patient characteristics
Of 1058 patients who had undergone curative resection for
EGC between May 2005 and April 2007, 115 (10.9%) were lost
to follow-up due to insufficient information. Among the
remaining 943 patients, data for all the necessary variables were
available for 930 patients. Descriptive statistics for the external
validation dataset are summarized and compared with those for
the nomogram development dataset in Table 1. The differences
between the two cohorts were a relatively older age and smaller
tumor size in the external validation set compared with the
nomogram development set: median age 58 years (range
19–91) and tumor size 2.5 cm (61.7) in the external validation
set compared with 57 years (range 23–89) and 2.7 cm (61.6) in
the nomogram development set. In addition, a lower tumor
location and more undifferentiated histology were observed
in the external validation set. The two cohorts were similar in
other clinicopathologic factors.
Among 930 patients, 11 (1.1%) experienced recurrence
during the follow-up period. The median time to recurrence
was 26.4 months (range 10.7–39.0 months) and four patients
(36.4%) had recurrence within 2 years. Hematogenous
recurrence was the predominant recurrence pattern; 7 (63.6%)
of 11 recurred EGC patients had hematogenous recurrence,
whereas 4 had locoregional recurrence. Table 2 shows
a comparison of characteristics between the ‘no recurrence
group’ and the ‘recurrence group’ in the external validation
set. The recurrence group had a higher rate of lymph
node metastasis (54.5%) compared with that of the no
recurrence group (9.9%). The difference in lymph node
status between these two groups was statistically significant
(P = 0.003).
nomogram
The mean nomogram score of the nomogram development
set and the external validation set is shown in Figure 3.
The nomogram development set had a slightly higher
nomogram score (208 6 34.4) than the external validation set
(203.7 6 32.7, P £ 0.0001). Among the external validation set,
Figure 2. The early gastric cancer nomogram available in Hyper Text
Markup Language format.
Table 1. Descriptive statistics of early gastric cancer patient cohorts
from nomogram development set and external validation set. The two
cohorts demonstrated statistical differences in terms of age, tumor size,
tumor location, and histology.
Nomogram
development
set (n = 2923)
External
validation
set (n = 930)
P value
Age (years) <0.0001
Median (range) 57 (19–91) 58 (23–89)
Gender, n (%) 0.372
Male 1912 (65.4) 622 (66.9)
Female 1011 (34.6) 308 (33.1)
Tumor size (cm) <0.0001
Mean 6 SD 2.5 6 1.7 2.7 6 1.6
Tumor location, n (%) <0.0001
Upper 362 (12.4) 57 (6.1)
Middle 1406 (48.1) 348 (37.4)
Lower 1155 (39.5) 525 (56.5)
Gross appearance, n (%) 0.832
Elevated 444 (15.2) 139 (14.9)
Nonelevated 2403 (82.2) 791 (85.1)
Histology, n (%) 0.027
Differentiated 1435 (49.1) 500 (53.8)
Undifferentiated 1435 (49.1) 430 (46.2)
Depth of invasion, n (%) 0.111
Mucosa 1485 (50.8) 505 (54.3)
Submucosa 1438 (49.2) 425 (45.7)
Lymph node status, n (%) 0.529
Negative 2601 (89.0) 834 (89.7)
Positive 322 (11.0) 96 (10.3)
SD, standard deviation.
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the mean nomogram score of the recurrence group was lower
than that of the no recurrence group (173.2 6 46.2 versus
204 6 32.5, respectively); however, this difference was not
statistically significant (P = 0.051).
To compare the nomogram-predicted outcome with the
actual outcome, patients in the external validation set were
divided into three risk groups according to their nomogram
score that predicted the probability of DFS. These cut-off
points were determined on the basis of the mean nomogram
score of the no recurrence group (209 6 33.4) and the
recurrence group (169.7 6 46.5) in the nomogram
development set as follows: high risk (<170 points, 102
patients), intermediate risk (170–209 points, 427 patients),
and low risk (>209 points, 401 patients). The descriptive
statistics for the three subgroups are listed in Table 3.
nomogram validation
When applied to the external validation set, the EGC
nomogram achieved a c-index of 0.70 (P = 0.02), meaning that
the accuracy of the nomogram for predicting recurrence is
70%. In addition, we carried out further discrimination using
the overall C index, which is the extension of C statistics to
survival analysis. The result of the overall C index at the 2-year
survival interval was 0.82 (P = 0.006, 95% CI 0.59–1.00), which
means that the accuracy of the EGC nomogram for predicting
2-year DFS rate is 82%.
Next, c2 goodness of fit analysis was carried out for
calibration, in which P > 0.05 would indicate a significant
good fit. The goodness of fit test showed that the nomogram
model had significantly good fit at 1- and 2-year survival
intervals (v2 = 4.0995, P = 0.998 and v2 = 11.7679, P = 0.879,
respectively), which means that the EGC nomogram is accurate
in predicting individual 1- and 2-year DFS in the external
validation set.
A subsequent calibration of the EGC nomogram was assessed
by comparing the nomogram-predicted DFS with the actual
survival in subgroups divided according to their nomogram
score. The predictions derived from the EGC nomogram
were then divided into three groups depending on their points.
A Kaplan–Meier DFS curve showed a significant difference
among these three subgroups (P = 0.001). Especially, in
comparison with the DFS curve between the ‘high-risk group’
and ‘low-risk group’, the DFS of the low-risk group was
statistically significantly higher than that of the high-risk group
(93.4% 4-year DFS in high-risk group versus 99.2% 4-year DFS
in low-risk group) (Figure 4). In addition, when we divided the
total patients of the external validation set into two groups
depending on whether the nomogram score was lower or
greater than 170, patients with a score <170 points (high-risk
group) also showed worse actual DFS compared with
patients who had a score >170 (intermediate-risk group
+ low-risk group) (Figure 5).
discussion
The recurrence-predicting EGC nomogram that was originally
developed in the Yonsei Cancer Center, YUHS, combines
clinicopathological and operative parameters to predict DFS
at 2, 5, and 10 years from curative resection of EGC. The EGC
nomogram was previously internally validated for accuracy
[10]. This study has provided external validation for our EGC
nomogram.
In the current study, the overall recurrence rate of EGC after
D2 gastrectomy was 1.1%, which was relatively lower than
results of previous reports [3–8] including our previous study
Table 2. Comparison between no recurrence group and recurrence
group in external validation set. The lymph node status was significantly
different between these two groups (P = 0.003)
No recurrence
group
(n = 919)
Recurrence
group
(n = 11)
P value
Age (years) 0.058
Median (range) 58 (23–89) 64 (49–77)
Gender, n (%) 0.112
Male 612 (66.6) 10 (91.9)
Female 307 (33.4) 1 (9.1)
Tumor size (cm) 0.322
Mean 6 SD 2.7 6 1.6 3.2 6 1.7
Tumor location, n (%) 0.772
Upper 56 (6.1) 1 (9.1)
Middle 344 (37.4) 4 (36.4)
Lower 519 (56.5) 6 (54.5)
Gross appearance, n (%) 0.999
Elevated 138 (15.0) 1 (9.1)
Nonelevated 781 (85.0) 10 (91.9)
Histology, n (%) 0.999
Differentiated 494 (53.8) 6 (54.5)
Undifferentiated 425 (46.2) 5 (45.5)
Depth of invasion, n (%) 0.124
Mucosa 502 (54.6) 3 (27.3)
Submucosa 417 (45.5) 8 (72.7)
Lymph node status, n (%) 0.003
Negative 828 (90.1) 5 (45.5)
Positive 91 (9.9) 6 (54.5)
SD, standard deviation.
Figure 3. Comparison of the early gastric cancer nomogram score
between the groups.
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(5-year DFS = 2.7%) [10]. This might be due to the relatively
short follow-up duration of the current study. The median
time to recurrence in the patients of the external validation
set was 26.4 months, which was similar to that in the
nomogram development set (26.5 months). The
clinicopathologic characteristics and DFS observed in the
nomogram development cohorts and external validation
cohorts were similar.
The prognosis after curative resection for EGC is currently
estimated using TNM (tumour–node–metastasis) staging from
the American Joint Committee on Cancer [14]. The stage
groupings are based on the depth of tumor invasion and the
number of lymph node metastases and stratify patients into risk
groups. However, this system does not provide sufficient
estimates for recurrence risk and survival outcomes because
most patients with EGC are diagnosed at an early stage (stage I
or II) and the recurrence rate of EGC after curative resection is
rare. In contrast to the staging system, prognostic nomograms
are designed explicitly for prediction [11]. They do not produce
risk groups; instead, they attempt to combine all proven
prognostic factors and quantify risk as precisely as possible.
Prognostic nomograms have been developed and validated for
prostate cancer, sarcoma, pancreatic cancer, and gastric cancer
[15–21]. Nomograms are able to evaluate a large number of
significant variables to better predict an individual patient’s
outcome. Improved prediction of patient outcome would be
useful for counseling patients and scheduling patient follow-up,
especially for the rare incidence of recurrence in EGC patients.
The EGC nomogram carried out well when applied to the
external validation set, with good individual discriminatory
Figure 4. Comparison of Kaplan–Meier disease-free survival curve of
patients stratified into three risk groups depending on their nomogram
score.
Figure 5. Comparison of Kaplan-Meier disease-free survival curve of
patients stratified into two risk groups depending on their nomogram
score.
Table 3. Stratification into three risk groups depending on nomogram
score.
High-risk
group
(n = 102)
Intermediate-
risk group
(n = 427)
Low-risk
group
(n = 401)
Age (years)
Median (range) 62.5 (36–81) 63 (28–89) 52 (23–84)
Gender, n (%)
Male 82 (80.4) 338 (79.2) 202 (50.4)
Female 20 (19.6) 89 (20.8) 199 (49.6)
Tumor size (cm)
Mean 6 SD 3.0 6 1.7 2.6 6 1.5 2.7 6 1.6
Tumor location, n (%)
Upper 2 (2.0) 28 (6.6) 27 (6.7)
Middle 23 (22.5) 88 (20.6) 237 (59.1)
Lower 77 (75.5) 311 (72.8) 137 (34.2)
Gross appearance, n (%)
Elevated 34 (33.3) 88 (20.6) 17 (4.2)
Nonelevated 68 (66.7) 339 (79.4) 384 (95.8)
Histology, n (%)
Differentiated 69 (67.6) 288 (67.4) 143 (35.7)
Undifferentiated 33 (32.4) 139 (32.6) 258 (64.3)
Depth of invasion, n (%)
Mucosa 10 (9.8) 229 (53.6) 266 (66.3)
Submucosa 93 (90.2) 198 (46.4) 135 (33.7)
Lymph node status, n (%)
Negative 29 (28.4) 406 (95.1) 399 (99.5)
Positive 73 (71.6) 21 (4.9) 2 (0.5)
Total score of nomogram
Mean 6 SD 140.2 6 22.5 192.2 6 11.4 232.0 6 16.0
Recurrence 5 4 2
The predictions derived from the nomogram were divided into three
groups depending on their scores: high risk (<170 points, 102 patients),
intermediate risk (170–209 points, 427 patients), and low risk (>209 points,
401 patients).
SD, standard deviation.
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properties and a good overall calibration. The validation was
accomplished by comparing the nomogram predictions for
each patient in the external validation set with actual outcome.
The c-index was 0.70 when the EGC nomogram was applied to
the external validation set (n = 930). The c-index of 0.70 in the
external validation set means that the recurrence-predicting
accuracy of the nomogram is 70%. It is considered significant.
We evaluated further discrimination methods to improve
and enhance the predictive accuracy of the EGC nomogram.
Although the nomogram discriminated well among patients in
the external validation sets by using only nomogram score and
status of recurrencean, insufficient number of recurrences
occurred due to the relatively short follow-up duration of this
study. Measuring discrimination in survival analyses such as the
Cox regression model is more difficult and ambiguous than in
logistic regression. Therefore, we evaluated the discrimination
of our EGC nomogram using the overall discrimination index
C (overall C), which was introduced by Harrell et al. [22].
The overall C is a natural extension of the ROC curve area to
survival analysis and its development was motivated by the
extension of the concept of the ROC curve area viewed through
the Mann–Whitney statistic. It measures the probability of
concordance (agreement) between the predicted and observed
outcomes in terms of length of survival of any two subjects.
The estimated value of the overall C at the 2-year survival
interval of our series was found to be 0.82 (P = 0.006, 95%
CI 0.59–1.00), which means the recurrence-predicting accuracy
of the EGC nomogram is 82%. Although not perfect, this
represents an encouraging level of predictive accuracy.
Calibration describes how closely the predicted probabilities
agree numerically with the actual outcomes. The goodness of fit
test showed that the nomogram model had a significantly
good fit at 1- and 2-year survival intervals (P = 0.998 and 0.879,
respectively). In addition, this was verified by a linear analysis
after grouping patients according to their nomogram-predicted
probabilities and then comparing the mean of the group
with the observed survival estimate. The predictions derived
from the nomogram were then divided into three groups
depending on their score, and the points defining each group
were arbitrarily determined on the basis of the mean
nomogram score of the no recurrence group and recurrence
group in the nomogram development set. The actual DFS of
the high-risk group (<170 points) was worst among the three
subgroups, as shown in the results. In addition, when we
divided the total patients of the external validation set into
two groups depending on whether the nomogram score was
lower or greater than 170, patients with a score <170 points
(high-risk group) also showed worse actual DFS compared
with patients who had a score >170 (intermediate-risk group
+ low-risk group). Therefore, the actual and predicted survival
outcomes showed good agreement, suggesting that the
survival predictions from the nomogram are well calibrated
externally.
The EGC nomogram showed a clear correlation between
nomogram score and predicted DFS in patients with nomogram
score <170. It indicated that a patient with a lower
nomogram score had worse predicted DFS than patients with
nomogram score <170, whereas predicted DFS was not
proportional to the increase in nomogram score in patients
with a nomogram score >170 points (data not shown). It
could be interpreted that the EGC nomogram is useful for
predicting recurrence of EGC in patients with a nomogram
score <170.
There are some limitations to our study. Despite its
widespread use, the Cox model may have difficulty representing
complex relationships, such as interactions in which a variable
has a different effect depending on the level(s) of other
varia4ble(s). In addition, it is impossible to include enough
predictive variables in a nomogram to give absolute
predictions. Known variables may not be included because
of the lack of numbers or observations, even though they are
considered important in some analyses. However, by taking
into account a greater number of known factors, this
postresection nomogram allows for a more realistic
approximation of whether an individual patient will suffer
recurrence within a defined period of time.
The ethnic group is also an important factor that cannot
be overlooked for prediction of EGC. This EGC nomogram
derived from one population (Korean) might not be applicable
to a different population (i.e. western countries). As our
understanding of the disease progresses, additional clinical,
pathologic, and biologic markers can be incorporated to
further refine this predictive tool.
conclusion
Our preexisting nomogram for predicting recurrence-free
survival of EGC after surgery was externally validated in this
study. For the individual patient, the nomogram predicts the
likelihood that a population of similar patients will survive for
a defined period of time. Although this is only a likelihood, the
nomogram provides a more accurate prediction of what the
patient might expect, as it takes into account factors that are
not included in a simple median survival analysis. For the
clinician, the nomogram might be helpful in tailoring
follow-up schedules or novel therapeutic strategies.
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